文献速递乳腺癌

CTS5整合临床变量预测雌激素受体阳性乳腺癌5年内分泌治疗后的远期远处复发

Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.
PubMed 文献 · J Clin Oncol · 2018-04-20

研究利用ATAC数据集(N=4,735)构建CTS5评分预测5年内分泌治疗后远期远处复发风险,并在BIG 1-98数据集(N=6,711)中验证。CTS5对远期远处复发具有显著预后价值,最终算法可识别42%年复发风险低于1%的女性。

要点

  • CTS5在ATAC和BIG 1-98队列中均对远期远处复发具有显著预后价值。
  • CTS5将风险分为低危(5–10年远处复发风险<5%)、中危(5%–10%)和高危(>10%)。
  • 最终CTS5算法识别42%年远处复发风险低于1%的女性,可据此告知延长内分泌治疗潜在价值有限。

核心结论

  • CTS5是一种基于临床常用信息的简易工具,在独立BIG 1-98研究中验证为对远期远处复发具有高度预后价值。
  • 最终CTS5算法识别42%年远处复发风险低于1%的女性,可告知其延长内分泌治疗潜在价值有限。

研究设计与样本

  • 利用ATAC数据集(N=4,735)构建5年后远处复发风险的预后评分,并在BIG 1-98数据集(N=6,711)中检验CTS5(ATAC)的效度。
  • 主要终点为完成预定内分泌治疗5年后的远期远处复发时间,采用Cox回归模型评估CTS5(ATAC)的预后效能。
  • 最终CTS5由ATAC与BIG 1-98的汇总数据推导。

主要发现

  • CTS5(ATAC)对远期远处复发在ATAC队列中具有显著预后价值(风险比2.47;95%CI 2.24–2.73;P< .001)。
  • CTS5(ATAC)在BIG 1-98验证队列中同样具有显著预后价值(风险比2.07;95%CI 1.88–2.28;P< .001)。
  • 验证队列中43%被归为低危,第5–10年观察到的远处复发率为3.6%(95%CI 2.7%–4.9%)。
  • 第5–10年,63%淋巴结阴性患者为低危,远处复发率3.9%(95%CI 2.9%–5.3%);1–3枚阳性淋巴结患者中24%为低危,远处复发率1.5%(95%CI 0.5%–3.8%)。

关键数值与推荐

  • 训练队列定义低危为第5–10年远处复发风险<5%,中危为5%–10%,高危为>10%。
  • 最终CTS5算法识别42%的女性年远处复发风险低于1%。

临床怎么用

  • 可依据CTS5对完成5年内分泌治疗且无复发的激素受体阳性乳腺癌患者进行远期远处复发风险分层。
  • 对CTS5判定为低危、尤其年远处复发风险低于1%者,可告知延长内分泌治疗潜在价值有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Estimating risk of late distant recurrence (DR) is an important goal for managing women with hormone receptor-positive breast cancer after 5 years of endocrine treatment without recurrence. We developed and validated a simple clinicopathologic tool (Clinical Treatment Score post-5 years [CTS5]) to estimate residual risk of DR after 5 years of endocrine treatment. Patients and Methods The ATAC (Arimidex, Tamoxifen, Alone or in Combination) data set (N = 4,735) was used to create a prognostic score for post-5-year risk of DR. Validity of CTS5 (ATAC) was tested in the BIG 1-98 data set (N = 6,711). Time to late DR, 5 years after finishing scheduled endocrine therapy, was the primary end point. Cox regression models estimated the prognostic performance of CTS5 (ATAC). Results CTS5 (ATAC) was significantly prognostic for late DR in the ATAC cohort (hazard ratio, 2.47; 95% CI, 2.24 to 2.73; P < .001) and BIG 1-98 validation cohort (hazard ratio, 2.07; 95% CI, 1.88 to 2.28; P < .001). CTS5 (ATAC) risk stratification defined in the training cohort as low (< 5% DR risk, years 5 to 10), intermediate (5% to 10%), or high (> 10%) identified 43% of the validation cohort as low risk, with an observed DR rate of 3.6% (95% CI, 2.7% to 4.9%) during years 5 to 10. From years 5 to 10, 63% of node-negative patients were low risk, with a DR rate of 3.9% (95% CI, 2.9% to 5.3%), and 24% with one to three positive nodes were low risk, with a DR rate of 1.5% (95% CI, 0.5% to 3.8%). A final CTS5 for future use was derived from pooled data from ATAC and BIG 1-98. Conclusion CTS5 is a simple tool based on information that is readily available to all clinicians. CTS5 was validated as highly prognostic for late DR in the independent BIG 1-98 study. The final CTS5 algorithm identified 42% of women with < 1% per-year risk of DR who could be advised of the limited potential value of extended endocrine therapy.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Dowsett M, Sestak I, Regan MM, et al. Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5. J Clin Oncol. 2018. PMID: 29676944. doi:10.1200/JCO.2017.76.4258

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。